Your browser doesn't support javascript.
loading
Cost-effectiveness of cognitive behavioural and personalized exercise interventions for reducing fatigue in inflammatory rheumatic diseases.
Chong, Huey Yi; McNamee, Paul; Bachmair, Eva-Maria; Martin, Kathryn; Aucott, Lorna; Dhaun, Neeraj; Dures, Emma; Emsley, Richard; Gray, Stuart R; Kidd, Elizabeth; Kumar, Vinod; Lovell, Karina; MacLennan, Graeme; Norrie, John; Paul, Lorna; Packham, Jonathan; Ralston, Stuart H; Siebert, Stefan; Wearden, Alison; Macfarlane, Gary; Basu, Neil.
Afiliação
  • Chong HY; Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
  • McNamee P; Health Economics Research Unit, Institute of Applied Health Sciences, University of Aberdeen, Aberdeen, UK.
  • Bachmair EM; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
  • Martin K; Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK.
  • Aucott L; Aberdeen Centre for Arthritis and Musculoskeletal Health (Academic Primary Care Group), University of Aberdeen, Aberdeen, UK.
  • Dhaun N; Centre of Healthcare and Randomised Trials (CHaRT), Health Service Research Unit, University of Aberdeen, Aberdeen, UK.
  • Dures E; Centre for Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh/British Heart Foundation Centre of Research Excellence, Edinburgh, UK.
  • Emsley R; Faculty of Health and Applied Sciences, University of the West of England, Bristol, UK.
  • Gray SR; Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
  • Kidd E; Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
  • Kumar V; Department of Rheumatology, Freeman's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Lovell K; Department of Rheumatology, Ninewells Hospital, NHS Tayside, Dundee, UK.
  • MacLennan G; School of Health Sciences, University of Manchester, Manchester, UK.
  • Norrie J; Centre of Healthcare and Randomised Trials (CHaRT), Health Service Research Unit, University of Aberdeen, Aberdeen, UK.
  • Paul L; Edinburgh Clinical Trials Unit, University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • Packham J; School of Health and Life Science, Glasgow Caledonian University, Glasgow, UK.
  • Ralston SH; Physiotherapy and Paramedicine, Haywood Rheumatology Centre, Stoke-on-Trent, UK.
  • Siebert S; Rheumatology and Bone Disease, University of Edinburgh, Western General Hospital, Edinburgh, UK.
  • Wearden A; Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK.
  • Macfarlane G; School of Health Sciences, University of Manchester, Manchester, UK.
  • Basu N; Aberdeen Centre for Arthritis and Musculoskeletal Health (Epidemiology Group), University of Aberdeen, Aberdeen, UK.
Rheumatology (Oxford) ; 62(12): 3819-3827, 2023 12 01.
Article em En | MEDLINE | ID: mdl-37018151
ABSTRACT

OBJECTIVES:

To estimate the cost-effectiveness of a cognitive behavioural approach (CBA) or a personalized exercise programme (PEP), alongside usual care (UC), in patients with inflammatory rheumatic diseases who report chronic, moderate to severe fatigue.

METHODS:

A within-trial cost-utility analysis was conducted using individual patient data collected within a multicentre, three-arm randomized controlled trial over a 56-week period. The primary economic analysis was conducted from the UK National Health Service (NHS) perspective. Uncertainty was explored using cost-effectiveness acceptability curves and sensitivity analysis.

RESULTS:

Complete-case analysis showed that, compared with UC, both PEP and CBA were more expensive [adjusted mean cost difference PEP £569 (95% CI £464, £665); CBA £845 (95% CI £717, £993)] and, in the case of PEP, significantly more effective [adjusted mean quality-adjusted life year (QALY) difference PEP 0.043 (95% CI 0.019, 0.068); CBA 0.001 (95% CI -0.022, 0.022)]. These led to an incremental cost-effectiveness ratio (ICER) of £13 159 for PEP vs UC, and £793 777 for CBA vs UC. Non-parametric bootstrapping showed that, at a threshold value of £20 000 per QALY gained, PEP had a probability of 88% of being cost-effective. In multiple imputation analysis, PEP was associated with significant incremental costs of £428 (95% CI £324, £511) and a non-significant QALY gain of 0.016 (95% CI -0.003, 0.035), leading to an ICER of £26 822 vs UC. The estimates from sensitivity analyses were consistent with these results.

CONCLUSION:

The addition of a PEP alongside UC is likely to provide a cost-effective use of health care resources.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicina Estatal / Doenças Reumáticas Tipo de estudo: Clinical_trials / Health_economic_evaluation Limite: Humans Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Medicina Estatal / Doenças Reumáticas Tipo de estudo: Clinical_trials / Health_economic_evaluation Limite: Humans Idioma: En Revista: Rheumatology (Oxford) Assunto da revista: REUMATOLOGIA Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido